Brain Circuits Underlying the Pathophysiology of Mood Disorders

Wayne C. Drevets MD

Janssen Research & Development, LLC



PHARMACEUTICAL COMPANIES


## Presenter's Disclosure of Interest

Presenter: Wayne C. Drevets, M.D.


- Sources of Current or Past Research Support
  - NIMH, MRC
  - Janssen Research & Development, LLC
  - NARSAD (BBRF)
  - Stanley Medical Research Institute
  - William K. Warren Foundation
  - Wellcome Trust
- Current Employment and Equity Interest
  - Janssen Research & Development, LLC , one of the Pharmaceutical Companies of Johnson & Johnson

Note: This presentation contains personal views and opinions which may not represent those of my employer or its affiliates.

### **Brain Regions Involved in Mood Disorders**



#### Areas of Abnormal Flow and Metabolism in MDD



PHARMACEUTICAL COMPANIES

Janssen

or Johmon Johmon Drevets WC. Annual Reviews in Medicine 1998; 49:341-61 Mood Disease Area Strategy

### Summary of Amygdala efferent projections

6 24' 24

TEa

EC

32

14

PrCO

ai

13a

6

STG

TEa

13

45

PrCO

10


High Medium

Low

Зb

Left: amygdaloid circuits involving the striatum, pallidum, thalamus and PFC, and output to the hypothalamus and brainstem.

**<u>Right</u>:** Areas of cerebral cortex that receive axonal projections from the amygdala.



Amaral D, et al. 1992; Price JL, Drevets WC, NPP Reviews, 2009


# Target for Course Modification in MDD? – More persistent disabling illness associated with grey matter loss in corticolimbic networks

Voxel-Based Morphometry: Reduced gray matter in chronic/ highly recurrent depression versus persistent remission

Subgenual Anterior Cingulate Cortex

Jansser


slice location Z = -11




Anterior Temporal cortex


Salvadore G, et al. NeuroImage, 2011; 54(4):2643-51


#### Neurocircuitry of Mood Disorders, Neurosurgical Sites for Tx refractory MDD




Persistent Reduction in Metabolism Pinpoints Corresponding Reduction in Cortex Volume Drevets et al; Nature 1997








#### **Recurrent Mood Disorders Show Dendritic Atrophy in Stress Related Brain Regions (e.g., medial PFC, hippocampus)**



janssen j

#### mPFC Activity a Key Determinant of Depression-like Behavior

(*LEFT*) Reduced expression of immediate early genes (IEG), zif268 (egr1), c-fos and arc, in ventral ACC (BA 24sg) of clinically depressed humans (postmortem), consistent with deficit in regional neuronal activity. (*RIGHT*) Mice subjected to chronic <u>social defeat stress</u> exhibit similar reductions in IEG expression in mPFC (though some changes not seen in defeated mice that escape the deleterious consequences of stress, i.e., resilient animals).




Mood Disease Area Strategy

#### mPFC Activity a Key Determinant of antidepressant responses

<u>Method</u>: Optogenetically drive "burst" patterns of cortical firing *in-vivo* using viral vectors to overexpress channel rhodopsin 2 (a light-activated cation channel) in mouse ventral mPFC

<u>Result</u>: In mice expressing a depressivelike phenotype, optogenetic stimulation of mPFC exerted antidepressant-like effects, without affecting general locomotor activity, anxiety-like behaviors, or social memory.


Covington et al J Neurosci 2010






## Chronic unpredictable stress (CUS) exposure decreases spine density in medial PFC, changes rapidly reversed by ketamine within 24 hrs








# Meta-Analysis of ketamine (single dose, 0.5 mg/kg IV) shows rapid antidepressant effect 24h post dose, with attenuation by one week

FIGURE 2. Forest Plots of Therapeutic Response Rates One Day and One Week After Initiation of Ketamine<sup>a</sup>

	Α	Statistics for Each Study					Odds Ratio and 95% CI			
		Odds	Lower	Upper						
	Study	ratio	limit	limit	Z-Value	p-Value				
Results one <u>day</u>	Diazgranados et al. (85)	26.053	1.359	499.339	2.164	0.030				→
	Lapidus et al. (84)	13.600	1.238	149.455	2.134	0.033				→
	Murrough et al. (87)	4.833	1.578	14.803	2.759	0.006				
post	Sos et al. (91)	15.294	1.610	145.305	2.374	0.018				→
ketamine	Zarate et al. (88)	79.545	3.762	1681.833	2.811	0.005				→
	Zarate et al. (86)	22.176	1.133	434.158	2.042	0.041				→
		9.865	4.366	22.293	5.503	0.000			-	
							0.01	0.1	i 10	100
								Control	Ketamine	
	В		Statistics for Each Study				Odds Ratio and 95% CI			
		Odds	Lower	Upper						
	Study	ratio	limit	limit	Z-Value	p-Value				
Results one <u>week</u> post	Diazgranados et al. (85)	5.000	0.426	58.636	1.281	0.200			•	-
	Lapidus et al. (84)	3.171	0.179	56.222	0.787	0.431			•	-
	Murrough et al. (87)	3.937	1.149	13.492	2.181	0.029				
	Sos et al. (91)	4.706	0.950	23.302	1.898	0.058				
ketamine	Zarate et al. (88)	19.783	1.060	369.109	1.999	0.046			•	→
	Zarate et al. (86)	3.222	0.176	58.849	0.789	0.430				-
		4.610	2.076	10.236	3.754	0.000				
							0.01	0.1	1 10	100
								Control	Ketamine	





#### **Synaptic Loss in Depression Countered by Synaptogenesis During Treatment with Ketamine**



janssen ()


### Subgenual (subcallosal) PFC loci for emotion processing and DBS






Microelectrode recording site for each emotion category responsive neuron. Red-disturbing, blue-sad, white-neutral, yellow-happy), green-exhilarating. *Laxton et al. Biol Psych 2013* 


Loci of electrode contacts loci in patients who responded to DBS (procedure was bilateral, so 2 circles of same color for each patient). C: Average location of active contact in responders (+SD). Hamani et al. J Neurosurgery 2009






Medial surface of human brain subgenual (sgACC & pregenual (pgACC) anterior cingulate C

Price & Drevets, TICS, 2012



#### Neuronal Coding of Implicit Emotion Categories in Subgenual (Subcallosal) PFC in Depressed Patients



(A) Responsive neurons of sgACC and adjacent vmPFC show specificity for complex emotion categories rather than valence or arousal alone (\*p<.001). (B) Preferential responsiveness for negative emotion categories over positive or neutral categories (\*p <.001).

56/136 neurons responded to IAPS stimuli, of which 32 responded to a single emotion category, of which 44% responded to disturbing, 22% to sad, 9.4% to neutral, 9.4% to happy images, 16% to exhilarating images. *Laxton et al. Biol Psychiatry, 2013* 




# Rostral anterior cingulate response to Sad vs Happy stimuli changes during sertraline treatment & predicts response

- In MDD, antidepressant-induced reversal of the negative processing bias is associated with shifts in the pattern of hemodynamic activity of pregenual and subgenual ACC.
- Under SSRI Tx the pre-treatment BOLD response of pregenual ACC to masked sad vs masked happy faces correlated with subsequent improvement in depression severity (r=0.67, p<0.05)</li>
- Pretreatment baseline activity of pregenual ACC predicts response to various antidepressant treatment modalities (including ketamine).
- Rostral ACC shares substantial anatomical connections with amygdala and hippocampus, through which they modulate neural and behavioral responses to emotional stimuli.

Pizzagalli, 2011. Neuropsychopharmacology Victor T, et al. Int. J. Psychopharmacology, 2013 Salvadore et al. Neuropsychopharmacology, 2010





Right Pregenual Anterior Cingulate Cortex (x, y, z = 14, 42, -5)




Mood Disease Area Strategy

# Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus






Strong QUIN immunoreactivity found only in vascular monocytes and microglia. Immunoreactive microglia showed smooth, ovoid or elongated cell form in controls, but numerous granular structure processes in depressives in aMCC and sACC.



### Subgenual anterior cingulate cortex activity predicts inflammation-associated mood change



Hemodynamic response to emotional faces during mood change and cytokine release under typhoid Vaccine

Harrison et al. **Biol Psychiatry** 2009

### **Complex Neuropsychiatric Disorders: Targeting Treatment at Multiple Levels**

Environment: e.g., "stressors" (psychological, physiological)



<u>Genes</u> Common susceptibility alleles of small effect (BDNF, P2X7, ANK3); Infrequent mutations of intermediate effect (K+ and Ca++ channels)

Proteins, Neurotransmitters & receptors (e.g., 5-HT, orexin), Hormones (e.g., cortisol, CRH, ghrelin/ leptin), Proinflammatory cytokines, chemokines, Autoantibodies, Kynurenine metabolites

<u>Cells</u> Glial and neuronal dysfunction, mitochondrial dysfunction; Microglial activation, Glia-based glutamate transport

Systems Abnormal function & information processing in interacting circuits & homeostatic systems regulating emotion, stress biology (e.g., glucocorticoid, immune, endocannabanoid) Behavior Complex interactions affecting emotional, motivational, cognitive, visceromotor domains; Illness course, treatment outcome, Comorbid psychiatric, medical syndromes

Mood

Disorders